Suraksha Diagnostic Limited has informed the Exchange about Transcript
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic reported Q3 FY26 revenue of INR 783.09 million, up 30.3% year-on-year, with EBITDA of INR 237.82 million (up 26.1%) at a margin of 30.6% and PAT of INR 72.41 million. For the nine-month period, revenue grew 21.86% to INR 2,313.81 million with EBITDA margin of 32.1%. Growth was driven by a 23% rise in patients served and 30.7% jump in tests performed. Management noted temporary margin compression due to pre-operative costs of 24 new centers (18 less than a year old), revising full-year EBITDA margin guidance from 33-34% to around 32%, with recovery expected by Q3 FY27. The company has 42 mature centers plus 12 newly commissioned and 6 in execution, with a target of 100 centers by FY28 and annual capex of INR 70 crore. The genomics vertical, Suraksha Sutra, is currently at an INR 2.1-2.2 crore monthly run rate, targeted at INR 4+ crore annually in FY27.
Strong revenue growth and clear expansion roadmap should support the stock narrative, but near-term margin pressure from new center costs is acknowledged. Investors should watch for margin recovery by Q3 FY27 and traction in the genomics vertical, which management calls a key differentiator against larger competitors.